Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s stock had its “overweight” rating reaffirmed by stock analysts at Barclays PLC in a report issued on Wednesday. They currently have a $155.00 target price on the biopharmaceutical company’s stock. Barclays PLC’s price objective indicates a potential upside of 53.34% from the stock’s current price.

A number of other analysts have also weighed in on the company. Leerink Swann set a $208.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, March 13th. JPMorgan Chase & Co. set a $170.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $177.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, March 27th. Cowen and Company reiterated an “outperform” rating and issued a $180.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, April 28th. Finally, Zacks Investment Research raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average price target of $167.01.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 3.40% during mid-day trading on Wednesday, reaching $101.08. 9,759,689 shares of the company traded hands. The firm has a market capitalization of $22.70 billion, a P/E ratio of 48.16 and a beta of 1.39. Alexion Pharmaceuticals has a 12-month low of $98.63 and a 12-month high of $157.02. The company’s 50 day moving average price is $119.88 and its 200 day moving average price is $124.31.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The business had revenue of $870 million for the quarter, compared to analyst estimates of $826.63 million. During the same quarter last year, the firm posted $1.11 earnings per share. The business’s revenue was up 24.3% compared to the same quarter last year. Equities research analysts predict that Alexion Pharmaceuticals will post $5.31 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Rating Reiterated by Barclays PLC” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/24/alexion-pharmaceuticals-inc-alxn-rating-reiterated-by-barclays-plc.html.

In other Alexion Pharmaceuticals news, Director Leonard Bell sold 2,738 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $131.71, for a total value of $360,621.98. Following the sale, the director now owns 391,910 shares in the company, valued at $51,618,466.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Clare Carmichael sold 2,179 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $131.66, for a total value of $286,887.14. Following the completion of the sale, the executive vice president now owns 33,980 shares in the company, valued at approximately $4,473,806.80. The disclosure for this sale can be found here. Insiders sold 11,476 shares of company stock worth $1,504,601 in the last 90 days. Company insiders own 4.41% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Wetherby Asset Management Inc. increased its stake in Alexion Pharmaceuticals by 2.1% in the second quarter. Wetherby Asset Management Inc. now owns 10,068 shares of the biopharmaceutical company’s stock worth $1,176,000 after buying an additional 208 shares in the last quarter. Bank of Montreal Can acquired a new stake in Alexion Pharmaceuticals during the second quarter worth approximately $34,314,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its stake in Alexion Pharmaceuticals by 7.0% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 21,300 shares of the biopharmaceutical company’s stock worth $4,063,000 after buying an additional 1,400 shares in the last quarter. Fourth Swedish National Pension Fund increased its stake in Alexion Pharmaceuticals by 1.4% in the fourth quarter. Fourth Swedish National Pension Fund now owns 44,997 shares of the biopharmaceutical company’s stock worth $8,583,000 after buying an additional 610 shares in the last quarter. Finally, Commonwealth Equity Services increased its stake in Alexion Pharmaceuticals by 2.5% in the fourth quarter. Commonwealth Equity Services now owns 3,846 shares of the biopharmaceutical company’s stock worth $734,000 after buying an additional 94 shares in the last quarter. Institutional investors own 94.98% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

12 Month Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.